- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-673/18: Judgment of the Court (Grand Chamber) of 9 July 2020 (request for a preliminary ruling from the Cour d’appel de Paris — France) — Santen SAS v Directeur général de l’Institut national de la propriété industrielle (Reference for a preliminary ruling — Medicinal product for human use — Supplementary protection certificate for medicinal products — Regulation (EC) No 469/2009 — Article 3(d) — Conditions for the grant of a certificate — Obtaining the first authorisation to place the product on the market as a medicinal product — Authorisation to place on the market a new therapeutic application of a known active ingredient)
ECLI:EU:UNKNOWN:62018CA0673
62018CA0673
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
31.8.2020 *
(Case C-673/18) (1)
(Reference for a preliminary ruling - Medicinal product for human use - Supplementary protection certificate for medicinal products - Regulation (EC) No 469/2009 - Article 3(d) - Conditions for the grant of a certificate - Obtaining the first authorisation to place the product on the market as a medicinal product - Authorisation to place on the market a new therapeutic application of a known active ingredient)
(2020/C 287/04)
Language of the case: French
Referring court
Parties to the main proceedings
Applicant: Santen SAS
Defendant: Directeur général de l’Institut national de la propriété industrielle
Operative part of the judgment
Article 3(d) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products must be interpreted as meaning that a marketing authorisation cannot be considered to be the first marketing authorisation, for the purpose of that provision, where it covers a new therapeutic application of an active ingredient, or of a combination of active ingredients, and that active ingredient or combination has already been the subject of a marketing authorisation for a different therapeutic application.
(1) OJ C 25, 21.1.2019.